MicroRNA-300 decreases cell viability, inhibits migration and promotes apoptosis of osteosarcoma cells via downregulation of Twist1

Jia,Jinpeng; Yin,Pei; Han,Gang; Xu,Meng; Wang,Wei; Bi,Wenzhi

doi:10.3892/mmr.2017.7023

MicroRNA-300 decreases cell viability, inhibits migration and promotes apoptosis of osteosarcoma cells via downregulation of Twist1

Authors:
- Jinpeng Jia
- Pei Yin
- Gang Han
- Meng Xu
- Wei Wang
- Wenzhi Bi
View Affiliations

Affiliations: Department of Orthopaedics, General Hospital of Chinese People's Liberation Army, Beijing 100853, P.R. China, Department of Nephrology, First Affiliated Hospital of PLA General Hospital, Beijing 100037, P R. China
Published online on: July 17, 2017 https://doi.org/10.3892/mmr.2017.7023
Pages: 3613-3618

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is the most frequently occurring pediatric bone malignancy in the world. Numerous miRNAs have previously been demonstrated to participate in the initiation and development of OS. The present study aimed to reveal the role of microRNA‑300 (miR‑300) in OS cells and elucidate the underlying mechanism involved. The expression of miR‑300 in the MG63 human OS cell line was monitored via quantitative polymerase chain reaction (qPCR). Following transfection with miR‑300 mimic, miR‑300 inhibitor or scramble control, MG63 cell viability, migration and apoptosis were respectively measured by 3‑(4,5‑dimethyl‑2‑thiazolyl)‑2,5‑diphenyltetrazolium bromide (MTT), modified two‑chamber migration assay and flow cytometry. Dual‑Luciferase reporter assays, qPCR and western blot analysis were subsequently performed to verify whether Twist1 was a direct target of miR‑300. Furthermore, the expression levels of nuclear factor (NF)‑κB pathway proteins were detected via western blot analysis. In MG63 cells, miR‑300 was effectively overexpressed or suppressed by transfection with miR‑300 mimic or inhibitor, respectively (P<0.001). Overexpression of miR‑300 significantly suppressed cell viability and migration, whereas it enhanced apoptotic rate (P<0.001). miR‑300 suppression exhibited contrary results (P<0.05, P<0.01 or P<0.001). Twist1 was demonstrated to act as a direct target of miR‑300, and was negatively regulated by miR‑300. In addition, miR‑300 overexpression downregulated the expression of the primary factors involved in the NF‑κB signaling pathway. These effects on OS cell proliferation and apoptosis may be due to the miR‑300 targeting of Twist1 and the suppressive effect on the NF‑κB signaling pathway.

View Figures

View References

1	Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
2	Peng L: Progress in the treatment of osteosarcoma. Int J Orthop. 29:91–93. 2008.
3	Qiu Z and Liao Q: Progress of osteosarcoma therapy. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 24:1469–1475. 2010.(In Chinese). PubMed/NCBI
4	Jones-Rhoades MW and Bartel DP: Computational identification of plant micrornas and their targets, including a stress-induced miRNA. Mol Cell. 14:787–799. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
6	Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B and Bagni C: The fragile X syndrome protein FMRP associates with BC1 RNA and Regulates the translation of specific mRNAat synapses. Cell. 112:317–327. 2003. View Article : Google Scholar : PubMed/NCBI
7	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
8	Liu X, Liu L, Xu Q, Wu P, Zuo X and Ji A: MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Ther. 12:573–580. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhou F, Li Y, Hao Z, Liu X, Chen L, Cao Y, Liang Z, Yuan F, Liu J, Wang J, et al: MicroRNA-300 inhibited glioblastoma progression through ROCK1. Oncotarget. 7:36529–36538. 2016. View Article : Google Scholar : PubMed/NCBI
10	Nairismägi ML, Füchtbauer A, Labouriau R, Bramsen JB and Füchtbauer EM: The proto-oncogene TWIST1 is regulated by microRNAs. PLos One. 8:e660702013. View Article : Google Scholar : PubMed/NCBI
11	Sánchez-Tilló E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A and Postigo A: EMT-activating transcription factors in cancer: Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456. 2012. View Article : Google Scholar : PubMed/NCBI
12	Cho WH, Lee HJ, Choi YJ, Oh JH, Kim HS and Cho HS: Capsaicin induces apoptosis in MG63 human osteosarcoma cells via the caspase cascade and the antioxidant enzyme system. Mol Med Rep. 8:1655–1662. 2013.PubMed/NCBI
13	Zhang N, Su Y and Xu L: Targeting PKCε by miR-143 regulates cell apoptosis in lung cancer. FEBS Lett. 587:3661–3667. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shi W, Bruce J, Lee M, Yue S, Rowe M, Pintilie M, Kogo R, Bissey PA, Fyles A, Yip KW and Liu FF: MiR-449a promotes breast cancer progression by targeting CRIP2. Oncotarget. 7:18906–18918. 2016. View Article : Google Scholar : PubMed/NCBI
15	Rojas RE, Balaji KN, Subramanian A and Boom WH: Regulation of human CD4(+) alphabeta T-cell-receptor-positive (TCR(+)) and gammadelta TCR(+) T-cell responses to Mycobacterium tuberculosis by interleukin-10 and transforming growth factor beta. Infect Immun. 67:6461–6472. 1999.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, et al: Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 182:426–432. 2010. View Article : Google Scholar : PubMed/NCBI
18	Ambros V: microRNAs: Tiny regulators with great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
19	Wang GC, He QY, Tong DK, Wang CF, Liu K, Ding C, Ji F and Zhang H: MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4. J Bone Oncol. 5:51–56. 2016. View Article : Google Scholar : PubMed/NCBI
20	Lin BC, Huang D, Yu CQ, Mou Y, Liu YH, Zhang DW and Shi FJ: MicroRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1. Med Sci Monit. 22:1761–1765. 2016. View Article : Google Scholar : PubMed/NCBI
21	Geng S, Gu L, Ju F, Zhang H, Wang Y, Tang H, Bi Z and Yang C: MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. J Cell Mol Med. 20:1611–1619. 2016. View Article : Google Scholar : PubMed/NCBI
22	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
23	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
24	Xu F, Gao J, Zhang Z, Ge J, Wei Z and Cheng W: Expression of miRNA-300 in urothelial carcinoma of the bladder. J Medical Res. 2012.
25	Lin W: A preliminary study of miRNA-300 regulation in invasion and proliferation of colorectal cancer (unpublished PhD thesis). Third Military Medical University. 2015.(In Chinese).
26	Karbasy SH, Taheriazam A, Mirghasemi A, Sedaghati F, Shakeri M, Yahaghi E and Bahador R: RETRACTED ARTICLE: Upregulation of miR-300 and downregulation of miR-125b act as potential predictor biomarkers in progression, metastasis, and poor prognosis of osteosarcoma. Tumor Biol. 2015.(Epub ahead of print).
27	Xue Z, Zhao J, Niu L, An G, Guo Y and Ni L: Up-regulation of MiR-300 promotes proliferation and invasion of osteosarcoma by targeting BRD7. PLoS One. 10:e01276822015. View Article : Google Scholar : PubMed/NCBI
28	Banzhaf-Strathmann J and Edbauer D: Good guy or bad guy: The opposing roles of microRNA 125b in cancer. Cell Commun Signal. 12:302014. View Article : Google Scholar : PubMed/NCBI
29	Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH and Hannon GJ: Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 13:2207–2217. 1999. View Article : Google Scholar : PubMed/NCBI
30	Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ and Yun JP: miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis. 35:469–478. 2014. View Article : Google Scholar : PubMed/NCBI
31	Nairismägi ML, Füchtbauer A, Labouriau R, Bramsen JB and Füchtbauer EM: The protooncogene TWIST1 is regulated by microRNAs. PLoS One. 8:e660702013. View Article : Google Scholar : PubMed/NCBI
32	Dong P, Kaneuchi M, Watari H, Sudo S and Sakuragi N: MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog. 53:349–359. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhou Y, Zang X, Huang Z and Zhang C: TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett. 5:857–861. 2013.PubMed/NCBI
34	Wu J, Liao Q, He H, Da Z and Ke Y: TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog. 53:440–446. 2014. View Article : Google Scholar : PubMed/NCBI
35	Xu G, Shen J, Yu A, Wang H, Man TK and Lau CC: Abstract 3402: Knockdown of TWIST1 increases chemosensitivity of osteosarcoma cells. Cancer Res. 70:34022010. View Article : Google Scholar : PubMed/NCBI
36	Wullaert A, Verstrepen L, Van Huffel S, Adib-Conquy M, Cornelis S, Kreike M, Haegman M, El Bakkouri K, Sanders M, Verhelst K, et al: LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-kappaB activation. J Biol Chem. 282:81–90. 2007. View Article : Google Scholar : PubMed/NCBI
37	Zhao Y, Li Z, Wang W, Zhang H, Chen J, Su P, Liu L and Li W: Naringin protects against cartilage destruction in osteoarthritis through repression of NF-κB signaling pathway. Inflammation. 39:385–392. 2016. View Article : Google Scholar : PubMed/NCBI
38	Horikawa T, Yang J, Kondo S, Yoshizaki T, Joab I, Furukawa M and Pagano JS: Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res. 67:1970–1983. 2007. View Article : Google Scholar : PubMed/NCBI
39	Lv N, Shan Z, Gao Y, Guan H, Fan C, Wang H and Teng W: Twist1 regulates the epithelial-mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma. Endocrine. 51:469–477. 2016. View Article : Google Scholar : PubMed/NCBI
40	Sethi G, Ahn KS and Aggarwal BB: Targeting nuclear factor-kappa B activation pathway by thymoquinone: Role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 6:1059–1070. 2008. View Article : Google Scholar : PubMed/NCBI
41	Brandwood CP, Hoyland JA, Hillarby MC, Berry JL, Davies M, Selby PL and Mee AP: Apoptotic gene expression in Paget's disease: A possible role for Bcl-2. J Pathol. 201:504–512. 2003. View Article : Google Scholar : PubMed/NCBI